Denosumab - a new option in the treatment of osteoporosis

Abstract

Denosumab is the international name of a human, monoclonal antibody approved for the treatment of osteoporosis. This antibody is
associated with RANK ligand (RANKL), inactivating it. In consequence, the formation and survival of osteoclasts are suppressed, leading
to their apoptosis. All this results in lower bone resorption, while bone mineral density (BMD) increases.
Denosumab also reduces the risk of vertebral and non-vertebral fractures. This agent is similarly effective in various stages of renal function
impairment; it does not impair fracture healing processes nor contribute to atherosclerosis progression in patients with high cardiovascular
risks. Following an analysis of adverse effects, performed in the FREEDOM study (in which it was demonstrated that the incidence
of the majority of adverse effects observed in the course of denosumab use was similar to that in the placebo group), its safety for
patients can definitely be confirmed. (Pol J Endocrinol 2011; 62 (1): 79-83)